Evidence map›Paper›PMID 35241563›Full record

Observational studyIn vivo (Athens, Greece)

The Role of Programmed Cell Death Receptor 1 in Lung Cancer.

Dumitru Cristinel Badiu, Anca Zgura, Claudia Mehedintu, Bogdan Haineala, Rodica Anghel, Xenia Bacinschi

Open access · diamondAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 57% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Dumitru Cristinel BadiuGeneral Surgery Department, "Bagdasar Arseni" Clinical Emergency Hospital, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
Anca ZguraDepartment of Obstetrics-Radiotherapy, Prof. Dr. Alexandru Trestioreanu Institute of Oncology, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania; medicanca@gmail.com.
Claudia MehedintuDepartment of Obstetrics and Gynecology, Malaxa Clinical Hospital, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
Bogdan HainealaDepartment of Urology, "Fundeni" Clinical Institute, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
Rodica AnghelDepartment of Obstetrics-Radiotherapy, Prof. Dr. Alexandru Trestioreanu Institute of Oncology, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
Xenia BacinschiDepartment of Obstetrics-Radiotherapy, Prof. Dr. Alexandru Trestioreanu Institute of Oncology, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
Carol Davila University of Medicine and Pharmacy · ROInstitutul Oncologic Bucuresti · RO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimLung cancer is the most common cancer worldwide. Cancer immunotherapy is the activation of the immune system against cancer. The latest method of immunotherapy involves immune checkpoint inhibitors. Increased levels of programmed death ligand 1 (PD-L1) expression were observed on non-small-cell lung cancer. The association between PD-L1 expression and clinicopathological characteristics in lung cancer is still unclear. PATIENTS AND

methodsThis is a cross-sectional, observational study that evaluated a sample of 41 lung cancer patients diagnosed between March 2019 and December 2020. PD-L1 tumor expression is described as a percentage.

resultsPatients were diagnosed with non-microcellular lung cancer and aged 37 to 87 years. Most patients were diagnosed with adenocarcinoma. According to the analysis, the average age of patients with negative PD-L1 tumors was 65.6 years, and of those with positive PD-L1 tumors was 63.6 years. The average value of the tumor proportion score for males was 26.97%, and for females 25.55%.

conclusionNo correlation was found between PD-L1 tumor expression and the age and sex of patients.

Indexed as

AdenocarcinomaCarcinoma, Non-Small-Cell LungLung NeoplasmsAdultAgedAged, 80 and overApoptosisB7-H1 AntigenBiomarkers, TumorCross-Sectional StudiesFemaleHumansMaleMiddle AgedB7-H1 AntigenBiomarkers, TumorCD274 protein, humanchemotherapyimmune cellsLung cancerlymphocytesprogrammed death 1

Identifiers

PMID35241563
PMCPMC8931921
OpenAlexW4214918016

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.